計劃書編號99824
尚未開始召募
Phase III
召募中3
-
試驗委託 / 贊助單位名稱
Ｈ. Lundbeck A/S; 和安行
-
臨床試驗規模
-
更新日期
2026/02/01
試驗主持人及試驗醫院
適應症
Mechanism: Sertindole as a antipsychotic drugs , is derived from its selective inhibitory effect on mesolimbic dopaminergic neurons and is due to balanced inhibitory effects on central dopamine D2 and serotonin 5HT2 receptors as on a1-adrengic receptors.
Indications: schizophrenia. Due to cardiovascular safety concerns, sertindole should only be used for patients intolerant to at least one other antipsychotic agent. Sertindole should not be used in emergency situations for urgent relief of symptoms in acutely disturbed patients
試驗目的
在正常使用狀況下，比較Sertindole與Risperidone的安全性
藥品名稱
主成份
Sertindole
劑型
劑量
4,8,12,16,20,24
評估指標
主要納入條件
試驗計畫預計收納受試者人數
-
台灣人數
140 人
-
全球人數
100000 人
